{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:42:11Z","timestamp":1784634131419,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40263-023-01042-3","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T08:02:45Z","timestamp":1701244965000},"page":"1099-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct03904576","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Markus","family":"Goettel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Fuertig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome Rebecca","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"1","key":"1042_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/s41467-020-15920-7","volume":"11","author":"WZ Liu","year":"2020","unstructured":"Liu WZ, Zhang WH, Zheng ZH, Zou JX, Liu XX, Huang SH, et al. Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced anxiety. Nat Commun. 2020;11(1):2221.","journal-title":"Nat Commun"},{"key":"1042_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jad.2015.05.052","volume":"184","author":"U Lueken","year":"2015","unstructured":"Lueken U, Straube B, Yang Y, Hahn T, Beesdo-Baum K, Wittchen HU, et al. Separating depressive comorbidity from panic disorder: a combined functional magnetic resonance imaging and machine learning approach. J Affect Disord. 2015;184:182\u201392.","journal-title":"J Affect Disord"},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.psychres.2018.07.019","volume":"269","author":"Z Wu","year":"2018","unstructured":"Wu Z, Cao L, Peng D, Mellor D, Zhang C, Li H, et al. The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. Psychiatry Res. 2018;269:251\u20137.","journal-title":"Psychiatry Res"},{"issue":"9","key":"1042_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/da.21919","volume":"29","author":"P Zwanzger","year":"2012","unstructured":"Zwanzger P, Domschke K, Bradwejn J. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety. 2012;29(9):762\u201374.","journal-title":"Depress Anxiety"},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00213-007-0738-7","volume":"192","author":"D Eser","year":"2007","unstructured":"Eser D, Sch\u00fcle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, et al. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacol. 2007;192:479\u201387.","journal-title":"Psychopharmacol"},{"issue":"8","key":"1042_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.neubiorev.2005.05.008","volume":"29","author":"H Wang","year":"2005","unstructured":"Wang H, Wong PT, Spiess J, Zhu YZ. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev. 2005;29(8):1361\u201373.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1042_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/070674379003500115","volume":"35","author":"J Bradwejn","year":"1990","unstructured":"Bradwejn J, Koszycki D, Meterissian G. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry. 1990;35(1):83\u20135.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"1042_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.npp.1300131","volume":"28","author":"P Zwanzger","year":"2003","unstructured":"Zwanzger P, Eser D, Aicher S, Sch\u00fcle C, Baghai TC, Padberg F, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic\u2013pituitary\u2013adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28(5):979\u201384.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"1042_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S0006-3223(98)00348-5","volume":"45","author":"M Javanmard","year":"1999","unstructured":"Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry. 1999;45(7):872\u201382.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1042_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF02244846","volume":"114","author":"J Bradwejn","year":"1994","unstructured":"Bradwejn J, Koszycki D, Cou\u00ebtoux du Tertre A, Paradis M, Bourin M. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology. 1994;114(2):257\u201361.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1042_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0924-977X(96)00018-1","volume":"6","author":"HJGM van Megen","year":"1996","unstructured":"van Megen HJGM, Westenberg HGM, Den Boer JA, Kahn R. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Euro Neuropsychopharmacol. 1996;6(3):187\u201394.","journal-title":"Euro Neuropsychopharmacol."},{"issue":"4","key":"1042_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.31887\/DCNS.2011.13.4\/mkellner","volume":"13","author":"M Kellner","year":"2011","unstructured":"Kellner M. Experimental panic provocation in healthy man\u2014a translational role in anti-panic drug development? Dialogues Clin Neurosci. 2011;13(4):485\u201393.","journal-title":"Dialogues Clin Neurosci"},{"issue":"18","key":"1042_CR13","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.3390\/molecules26185657","volume":"26","author":"JF Rehfeld","year":"2021","unstructured":"Rehfeld JF. Cholecystokinin and panic disorder: reflections on the history and some unsolved questions. Molecules. 2021;26(18):5657.","journal-title":"Molecules"},{"issue":"7","key":"1042_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpsyc.1991.01810310021005","volume":"48","author":"J Bradwejn","year":"1991","unstructured":"Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991;48(7):603\u201310.","journal-title":"Arch Gen Psychiatry"},{"issue":"2\u20133","key":"1042_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0165-0327(03)00110-1","volume":"80","author":"D Koszycki","year":"2004","unstructured":"Koszycki D, Copen J, Bradwejn J. Sensitivity to cholecystokinin-tetrapeptide in major depression. J Affect Disord. 2004;80(2\u20133):285\u201390.","journal-title":"J Affect Disord"},{"issue":"3","key":"1042_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/jn.00025.2011","volume":"106","author":"S Wang","year":"2011","unstructured":"Wang S, Zhang AP, Kurada L, Matsui T, Lei S. Cholecystokinin facilitates neuronal excitability in the entorhinal cortex via activation of TRPC-like channels. J Neurophysiol. 2011;106(3):1515\u201324.","journal-title":"J Neurophysiol"},{"issue":"4","key":"1042_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.biopsych.2012.09.004","volume":"73","author":"G Leicht","year":"2013","unstructured":"Leicht G, Mulert C, Eser D, S\u00e4mann PG, Ertl M, Laenger A, et al. Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans. Biol Psychiatry. 2013;73(4):337\u201344.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1042_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0269881110367449","volume":"25","author":"T Schunck","year":"2011","unstructured":"Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazi\u00e8res A, et al. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI. J Psychopharmacol (Oxford, England). 2011;25(1):52\u20139.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"7","key":"1042_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.euroneuro.2012.08.011","volume":"23","author":"I T\u00f5ru","year":"2013","unstructured":"T\u00f5ru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(7):645\u201352.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"4","key":"1042_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s002130050201","volume":"129","author":"HJ van Megen","year":"1997","unstructured":"van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology. 1997;129(4):357\u201364.","journal-title":"Psychopharmacology"},{"issue":"6","key":"1042_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0029-1241798","volume":"42","author":"P Zwanzger","year":"2009","unstructured":"Zwanzger P, Eser D, Nothdurfter C, Baghai TC, M\u00f6ller HJ, Padberg F, et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry. 2009;42(6):266\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"1042_CR22","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1523\/JNEUROSCI.2274-13.2014","volume":"34","author":"A Riccio","year":"2014","unstructured":"Riccio A, Li Y, Tsvetkov E, Gapon S, Yao GL, Smith KS, et al. Decreased anxiety-like behavior and G\u03b1q\/11-dependent responses in the amygdala of mice lacking TRPC4 channels. J Neurosci Off J Soc Neurosci. 2014;34(10):3653\u201367.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"1042_CR23","unstructured":"Allen Institute for Brain Science. Allen Human Brain Atlas. 2004. https:\/\/human.brain-map.org. Accessed 31 May 2023."},{"issue":"4","key":"1042_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cell.2009.03.039","volume":"137","author":"A Riccio","year":"2009","unstructured":"Riccio A, Li Y, Moon J, Kim KS, Smith KS, Rudolph U, et al. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell. 2009;137(4):761\u201372.","journal-title":"Cell"},{"issue":"8","key":"1042_CR25","doi-asserted-by":"publisher","first-page":"e0136255-e","DOI":"10.1371\/journal.pone.0136255","volume":"10","author":"L-P Yang","year":"2015","unstructured":"Yang L-P, Jiang F-J, Wu G-S, Deng K, Wen M, Zhou X, et al. Acute treatment with a novel TRPC4\/C5 channel inhibitor produces antidepressant and anxiolytic-like effects in mice. PLoS\u00a0One. 2015;10(8):e0136255-e.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"1042_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191225","volume":"13","author":"S Just","year":"2018","unstructured":"Just S, Chenard BL, Ceci A, Strassmaier T, Chong JA, Blair NT, et al. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice. PLoS\u00a0One. 2018;13(1): e0191225.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"1042_CR27","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1016\/j.cub.2005.02.037","volume":"15","author":"SE Hyman","year":"2005","unstructured":"Hyman SE. Neurotransmitters. Curr Biol. 2005;15(5):R154\u20138.","journal-title":"Curr Biol"},{"key":"1042_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fphar.2012.00061","volume":"3","author":"EM Kawamoto","year":"2012","unstructured":"Kawamoto EM, Vivar C, Camandola S. Physiology and pathology of calcium signaling in the brain. Front Pharmacol. 2012;3:61.","journal-title":"Front Pharmacol"},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"S256","DOI":"10.1016\/j.euroneuro.2020.09.333","volume":"40","author":"R Fuertig","year":"2020","unstructured":"Fuertig R, Goettel M, H\u00f6fler J, Sharma VP. 450 A phase I single-rising-dose study of oral BI 1358894 in healthy male volunteers: safety, pharmacokinetics and food effect. Eur Neuropsychopharmacol. 2020;40:S256\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"1042_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094754","volume":"9","author":"N Pross","year":"2014","unstructured":"Pross N, Demazi\u00e8res A, Girard N, Barnouin R, Metzger D, Klein A, et al. Effects of changes in water intake on mood of high and low drinkers. PLoS\u00a0One. 2014;9(4): e94754.","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"1042_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/pcn.12665","volume":"72","author":"KD Young","year":"2018","unstructured":"Young KD, Zotev V, Phillips R, Misaki M, Drevets WC, Bodurka J. Amygdala real-time functional magnetic resonance imaging neurofeedback for major depressive disorder: a review. Psychiatry Clin Neurosci. 2018;72(7):466\u201381.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"20","key":"1042_CR32","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"7","key":"1042_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3109\/15622975.2011.604351","volume":"13","author":"C Demiralay","year":"2012","unstructured":"Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone. World J Biol Psychiatry. 2012;13(7):526\u201334.","journal-title":"World J Biol Psychiatry."},{"issue":"7534","key":"1042_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature14188","volume":"517","author":"PH Janak","year":"2015","unstructured":"Janak PH, Tye KM. From circuits to behaviour in the amygdala. Nature. 2015;517(7534):284\u201392.","journal-title":"Nature"},{"issue":"1","key":"1042_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1037\/a0035834","volume":"123","author":"D Mandell","year":"2014","unstructured":"Mandell D, Siegle GJ, Shutt L, Feldmiller J, Thase ME. Neural substrates of trait ruminations in depression. J Abnorm Psychol. 2014;123(1):35\u201348.","journal-title":"J Abnorm Psychol"},{"issue":"3","key":"1042_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.psc.2009.05.004","volume":"32","author":"EI Martin","year":"2009","unstructured":"Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin N Am. 2009;32(3):549\u201375.","journal-title":"Psychiatr Clin N Am"},{"key":"1042_CR37","unstructured":"Grimm S, Kreicher C, Paret C, Niedtfeld I, Mennes M, Just S et al. BI 1358894 leads to significant attenuation of brain activity in the Cortico-Limbic system as shown by task-based BOLD-fMRI using emotional paradigms in patients with MDD; 2020."},{"issue":"2","key":"1042_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/ajp.151.2.261","volume":"151","author":"J Bradwejn","year":"1994","unstructured":"Bradwejn J, Koszycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry. 1994;151(2):261\u20133.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"1042_CR39","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/0006-3223(95)00081-X","volume":"38","author":"J Bradwejn","year":"1995","unstructured":"Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry. 1995;38(11):742\u20136.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1042_CR40","first-page":"332","volume":"22","author":"J Shlik","year":"1997","unstructured":"Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci JPN. 1997;22(5):332\u201340.","journal-title":"J Psychiatry Neurosci JPN"},{"issue":"4","key":"1042_CR41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0893-133X(98)00124-9","volume":"21","author":"JL Abelson","year":"1999","unstructured":"Abelson JL, Liberzon I. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology. 1999;21(4):485\u201394.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1042_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/sj.npp.1300572","volume":"30","author":"D Eser","year":"2005","unstructured":"Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Sch\u00fcle C, et al. Panic induction with cholecystokinin-tetrapeptide (CCK-4) increases plasma concentrations of the neuroactive steroid 3\u03b1, 5\u03b1 tetrahydrodeoxycorticosterone (3\u03b1, 5\u03b1-THDOC) in healthy volunteers. Neuropsychopharmacology. 2005;30(1):192\u20135.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1042_CR43","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1017\/S1352465812000057","volume":"40","author":"S Helbig-Lang","year":"2012","unstructured":"Helbig-Lang S, Lang T, Petermann F, Hoyer J. Anticipatory anxiety as a function of panic attacks and panic-related self-efficacy: an ambulatory assessment study in panic disorder. Behav Cogn Psychother. 2012;40(5):590\u2013604.","journal-title":"Behav Cogn Psychother"},{"issue":"2","key":"1042_CR44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1037\/0022-006X.65.2.214","volume":"65","author":"NB Schmidt","year":"1997","unstructured":"Schmidt NB, Lerew DR, Trakowski JH. Body vigilance in panic disorder: Evaluating attention to bodily perturbations. J Consult Clin Psychol. 1997;65(2):214\u201320.","journal-title":"J Consult Clin Psychol"},{"issue":"11","key":"1042_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1037\/0003-066X.55.11.1247","volume":"55","author":"DH Barlow","year":"2000","unstructured":"Barlow DH. Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. Am Psychol. 2000;55(11):1247\u201363.","journal-title":"Am Psychol"},{"issue":"2","key":"1042_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1600-0447.2007.01001.x","volume":"116","author":"K Greaves-Lord","year":"2007","unstructured":"Greaves-Lord K, Ferdinand RF, Oldehinkel AJ, Sondeijker FE, Ormel J, Verhulst FC. Higher cortisol awakening response in young adolescents with persistent anxiety problems. Acta Psychiatr Scand. 2007;116(2):137\u201344.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1042_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/00016349009036154","volume":"69","author":"G Frick","year":"1990","unstructured":"Frick G, Bremme K, Sj\u00f6gren C, Lind\u00e9n A, Uvn\u00e4s-Moberg K. Plasma levels of cholecystokinin and gastrin during the menstrual cycle and pregnancy. Acta Obstet Gynecol Scand. 1990;69(4):317\u201320.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"1042_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0893-133X(98)00057-8","volume":"20","author":"JM Le Mell\u00e9do","year":"1999","unstructured":"Le Mell\u00e9do JM, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, et al. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology. 1999;20(1):81\u201391.","journal-title":"Neuropsychopharmacology"},{"key":"1042_CR49","doi-asserted-by":"crossref","unstructured":"Fuertig R, Goettel M, Herich L, Hoefler J, Wiebe ST, Sharma V. Effect of single and multiple ascending doses of BI 1358894 in healthy male volunteers on safety, tolerability and pharmacokinetics: two Phase I randomised studies (IN PRESS). CNS Drugs. 2023.","DOI":"10.1007\/s40263-023-01041-4"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01042-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01042-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01042-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T20:20:31Z","timestamp":1701980431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01042-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01042-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"26 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Boehringer Ingelheim (BI study numbers 1402-0005; NCT03904576). The funders of the study had a role in the study design, data analysis, data interpretation, and writing of the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MG, RF, SRM, SJ and AW are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. VS is an employee of Boehringer Ingelheim International GmbH. JdB is an employee of PRA Health Sciences. All authors did not receive any direct compensation relating to the development of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"To ensure independent interpretation of clinical study results, Boehringer Ingelheim grants all external authors access to all relevant material, including participant-level clinical study data, and relevant material as needed by them to fulfil their role and obligations as authors under the ICMJE criteria. Furthermore, clinical study documents (e.g., study report, study protocol, statistical analysis plan) and participant clinical study data are available to be shared after publication of the primary manuscript in a peer-reviewed journal and if regulatory activities are complete and other criteria met per the BI Policy on Transparency and Publication of Clinical Study Data: . Prior to providing access, documents will be examined, and, if necessary, redacted and the data will be de-identified, to protect the personal data of study participants and personnel, and to respect the boundaries of the informed consent of the study participants. Clinical Study Reports and Related Clinical Documents can also be requested via the link . All requests will be governed by a Document Sharing Agreement. Bona fide, qualified scientific and medical researchers may request access to de-identified, analyzable participant clinical study data with corresponding documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data are shared in a secured data-access system for a limited period of 1 year, which may be extended upon request. Researchers should use the   link to request access to study data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The trial was carried out in compliance with the clinical trial protocol and approved by an independent ethics committee of the participating center. All procedures were conducted in accordance with the principles of the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Each volunteer signed and dated an informed consent form according to the local regulatory and legal requirements and Good Clinical Practices.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MG, RF, SRM, SJ, VS, AW and JdB contributed to the study concept or design, and data analyses or interpretation. All authors contributed toward the preparation of the manuscript, approved the final submitted version, and agreed to be listed as authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}